The enrolment in the Phase III GENERATION HD1 study has been increased from 660 to 801 participants worldwide.
This change does not impact participants already enrolled in the study, but it allows for additional patients to enrol in the three existing study groups.
By enrolling more participants, Roche and Genentech will receive more data and increase the statistical power of the study!
Extended to China
Roche & Genentech are also pleased to announce that the GENERATION HD1 study is being extended to China. Read the entire letter from Roche Here!